Welcome!

News Feed Item

Urinary Tract Infections (UTI) Therapeutics - Pipeline Assessment and Market Forecasts to 2018

NEW YORK, Jan. 9, 2013 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Urinary Tract Infections (UTI) Therapeutics - Pipeline Assessment and Market Forecasts to 2018

http://www.reportlinker.com/p0843003/Urinary-Tract-Infections-UTI-Therapeutics---Pipeline-Assessment-and-Market-Forecasts-to-2018.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Therapy  

Urinary Tract Infections (UTI) Therapeutics - Pipeline Assessment and Market Forecasts to 2018

Summary

GlobalData, the industry analysis specialist, has released its new report, "Urinary Tract Infections (UTI) Therapeutics - Pipeline Assessment and Market Forecasts to 2018". The report is an essential source of information and analysis on the global Urinary Tract Infections Therapeutics market. The report identifies the key trends shaping and driving the global Urinary Tract Infections Therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global Urinary Tract Infections Therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

Scope

The report provides information on the key drivers and challenges of the Urinary Tract Infections Therapeutics market. Its scope includes -

- Annualized seven key markets (US, France, Germany, Italy, Spain, UK and Japan) Urinary Tract Infections Therapeutics market revenues data from 2005 to 2010, forecast for eight years to 2018.

- Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends by seven key markets. Pipeline candidates fall under major therapeutic classes.

- Analysis of the current and future competition in the seven key countries Urinary Tract Infections Therapeutics market.

- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.

- Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the Urinary Tract Infections Therapeutics market.

- Analysis of key recent licensing and partnership agreements in Urinary Tract Infections Therapeutics market

Reasons to buy

The report will enhance your decision making capability. It will allow you to -

- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline.

- Develop business strategies by understanding the trends shaping and driving the global Urinary Tract Infections Therapeutics market.

- Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global Urinary Tract Infections Therapeutics market in future.

- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.

- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.

- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

- What's the next big thing in the global Urinary Tract Infections Therapeutics market landscape? – Identify, understand and capitalize.

1 Table of Contents1 Table of Contents 31.1 List of Tables 51.2 List of Figures 62 UTI Therapeutics - Introduction 72.1 Overview 72.2 Classification of UTI 72.2.1 Site of Infection 82.2.2 Based On Symptoms 82.2.3 Based on Recurrence 82.2.4 Based on Complicating Factors 82.2.5 Based on Origin of Infection 82.3 Epidemiology 92.4 Etiology 102.5 Risk Factors 102.6 Signs and Symptoms 112.7 Pathophysiology of UTI 112.8 Diagnosis and Treatment of UTI 122.9 GlobalData Pipeline Report Guidance 163 UTI Therapeutics - Market Characterization 173.1 UTI Therapeutics Market Size (2005-2010) - Global 173.2 UTI Therapeutics Market Forecast (2010-2018) - Global 193.3 UTI Therapeutics Market Size (2005-2010) - The US 213.4 UTI Therapeutics Market Forecast (2010-2018) - The US 223.5 UTI Therapeutics Market Size (2005-2010) - France 233.6 UTI Therapeutics Market Forecast (2010-2018) - France 243.7 UTI Therapeutics Market Size (2005-2010) - Germany 253.8 UTI Therapeutics Market Forecast (2010-2018) - Germany 263.9 UTI Therapeutics Market Size (2005-2010) - Italy 273.10 UTI Therapeutics Market Forecast (2010-2018) - Italy 283.11 UTI Therapeutics Market Size (2005-2010) - Spain 293.12 UTI Therapeutics Market Forecast (2010-2018) - Spain 303.13 UTI Therapeutics Market Size (2005-2010) - The UK 313.14 UTI Therapeutics Market Forecast (2010-2018) - The UK 323.15 UTI Therapeutics Market Size (2005-2010) - Japan 333.16 UTI Therapeutics Market Forecast (2010-2018) - Japan 343.17 Drivers and Barriers for the UTI Therapeutics Market 353.17.1 Drivers for the UTI Therapeutics Market 353.17.2 Barriers for the UTI Therapeutics Market 353.18 Key Events Impacting the Future Market 363.19 Opportunity and Unmet Need 363.20 Key Takeaway 374 UTI Therapeutics Market - Competitive Assessment 384.1 Overview 384.1.1 Strategic Competitor Assessment 384.2 Profiles of Commonly Used Products in the UTI Therapeutics Market 394.2.1 Ciprofloxacin 394.2.2 Doribax (doripenem) 404.2.3 Invanz (ertapenem sodium) 414.2.4 Levaquin (levofloxacin) 424.2.5 Fosfomycin tromethamine 424.2.6 Macrobid/Macrodantin (nitrofurantoin) 434.2.7 Bactrim/Septra (trimethoprim/sulfamethoxazole) 444.3 Key Takeaway 445 UTI Therapeutics Market - Pipeline Assessment 455.1 Overview 455.2 Strategic Pipeline Assessment 455.2.1 UTI Therapeutics - Phase III Pipeline 465.2.2 UTI Therapeutics - Phase II Pipeline 465.2.3 UTI Therapeutics – Phase I Pipeline 465.3 UTI Pipeline by Mechanism of Action 475.4 UTI Technology Trends Analytical Framework 485.5 UTI Therapeutics - Late-stage Drugs under Clinical Development 495.6 Molecule Profile for Late-stage Drugs under Clinical Development 505.6.1 CXA-201 (CXA-101/tazobactam) 505.6.2 CAZ-AVI (Avibactam/ceftazidime) 505.7 Key Takeaway 516 UTI Therapeutics - Clinical Trials Mapping 526.1 Clinical Trials by Country (US, EU5 and Japan) 526.2 Clinical Trials by Phase 536.3 Clinical Trials by Trial Status 546.4 Overall Sponsors 556.5 Prominent Sponsors 566.6 Top Companies Participating in UTI Therapeutics Clinical Trials 577 UTI Therapeutics - Strategic Assessment 587.1 UTI Therapeutics - Implications for Future Market Competition 588 UTI Therapeutics - Future Players 598.1 Introduction 598.1.1 AstraZeneca PLC 598.1.2 Cubist Pharmaceuticals 618.1.3 Forest Laboratories 639 UTI Therapeutics - Licensing and Partnership Deals 6510 UTI Therapeutics - Appendix 6710.1 Definitions 6710.2 Acronyms 6710.3 Research Methodology 6810.3.1 Coverage 6810.3.2 Secondary Research 6810.3.3 Forecasting 6910.3.4 Primary Research 7110.3.5 Expert Panel Validation 7110.4 Contact Us 7110.5 Disclaimer 7110.6 Bibliography 72

List of Tables

Table 1: UTI - Prevalence, Major Markets, 2010 9Table 2: UTI Therapeutics Market, Global, Revenue ($bn), 2005-2010 17Table 3: UTI Therapeutics Market, Global, Forecast ($bn), 2010-2018 19Table 4: UTI Therapeutics Market, The US, Revenue ($m), 2005-2010 21Table 5: UTI Therapeutics Market, The US, Forecast ($bn), 2010-2018 22Table 6: UTI Therapeutics Market, France, Revenue ($m), 2005-2010 23Table 7: UTI Therapeutics Market, France, Forecast ($m), 2010-2018 24Table 8: UTI Therapeutics Market, Germany, Revenue ($m), 2005-2010 25Table 9: UTI Therapeutics Market, Germany, Forecast ($m), 2010-2018 26Table 10: UTI Therapeutics Market, Italy, Revenue ($m), 2005-2010 27Table 11: UTI Therapeutics Market, Italy, Forecast ($m), 2010-2018 28Table 12: UTI Therapeutics Market, Spain, Revenue ($m), 2005-2010 29Table 13: UTI Therapeutics Market, Spain, Forecast ($m), 2010-2018 30Table 14: UTI Therapeutics Market, The UK, Revenue ($m), 2005-2010 31Table 15: UTI Therapeutics Market, The UK, Forecast ($m), 2010-2018 32Table 16: UTI Therapeutics Market, Japan, Revenue ($m), 2005-2010 33Table 17: UTI Therapeutics Market, Japan, Forecast ($m), 2010-2018 34Table 18: UTI Therapeutics - Phase III Pipeline 46Table 19: UTI Therapeutics - Phase II Pipeline 46Table 20: UTI Therapeutics – Phase I Pipeline 46Table 21: UTI Therapeutics - Late-stage Drugs Under Clinical Development, 2011 49Table 22: UTI Therapeutics - Clinical Trials by Country, 2011 52Table 23: UTI Therapeutics - Clinical Trials by Phase, 2011 53Table 24: UTI Therapeutics - Clinical Trials by Status, 2011 54Table 25: UTI Therapeutics, Overall Sponsors, 2011 55Table 26: UTI Therapeutics - Prominent Sponsors, 2011 56Table 27: UTI Therapeutics - Top Companies Participating in Clinical Trials, 2011 57Table 28: AstraZeneca Infectious Disease Pipeline, 2011 61Table 29: Cubist Pharmaceuticals Infectious Disease Pipeline, 2011 62Table 30: Forest Laboratories - Infectious Disease Pipeline, 2011 64Table 31: Licensing and Partnership Deals 65

List of Figures

Figure 1: Classification of UTI 7Figure 2: Principal Pathogens of UTI 10Figure 3: Symptoms of UTI 11Figure 4: Diagnostic Approach to UTI in Adults 12Figure 5: Different Class of Antibiotics Used for UTI 13Figure 6: Diagnosis and Treatment of UTI 14Figure 7: Diagnosis and Treatment of UTI 15Figure 8: UTI Therapeutics Market, Global, Revenue ($bn), 2005-2010 17Figure 9: UTI Therapeutics, Market Share ($m, %), 2010 18Figure 10: UTI Therapeutics Market, Global, Forecast ($bn), 2010-2018 19Figure 11: UTI Therapeutics, Market Share ($m, %), 2018 20Figure 12: UTI Therapeutics Market, The US, Revenue ($m), 2005-2010 21Figure 13: UTI Therapeutics Market, The US, Forecast ($bn), 2010-2018 22Figure 14: UTI Therapeutics Market, France, Revenue ($m), 2005-2010 23Figure 15: UTI Therapeutics Market, France, Forecast ($m), 2010-2018 24Figure 16: UTI Therapeutics Market, Germany , Revenue ($m), 2005-2010 25Figure 17: UTI Therapeutics Market, Germany, Forecast ($m), 2010-2018 26Figure 18: UTI Therapeutics Market, Italy, Revenue ($m), 2005-2010 27Figure 19: UTI Therapeutics Market, Italy, Forecast ($m), 2010-2018 28Figure 20: UTI Therapeutics Market, Spain, Revenue ($m), 2005-2010 29Figure 21: UTI Therapeutics Market, Spain, Forecast ($m), 2010-2018 30Figure 22: UTI Therapeutics Market, The UK, Revenue ($m), 2005-2010 31Figure 23: UTI Therapeutics Market, The UK, Forecast ($m), 2010-2018 32Figure 24: UTI Therapeutics Market, Japan, Revenue ($m), 2005-2010 33Figure 25: UTI Therapeutics Market, Japan, Forecast ($m), 2010-2018 34Figure 26: UTI Therapeutics Market , Key Events Impacting the Future Market 36Figure 27: Opportunity and Unmet Need in the UTI Therapeutics Market, 2011 37Figure 28: UTI Therapeutics - Strategic Competitor Assessment, 2011 39Figure 29: UTI Therapeutics - Pipeline by Phase of Clinical Development, 2011 45Figure 30: UTI Therapeutics Market - Clinical Pipeline by Mechanism of Action, 2011 47Figure 31: Technology Trends Analytical Framework of the UTI Pipeline, 2011 48Figure 32: Technology Trends Analytical Framework of The UTI Therapeutics Pipeline - Description, 2011 49Figure 33: UTI Therapeutics - Clinical Trials by Country, 2011 52Figure 34: UTI Therapeutics - Clinical Trials by Phase, 2011 53Figure 35: UTI Therapeutics - Clinical Trials by Status, 2011 54Figure 36: UTI Therapeutics - Overall Sponsors, 2011 55Figure 37: UTI Therapeutics - Prominent Sponsors, 2011 56Figure 38: UTI Therapeutic Clinical Trial - Company Sponsors by Phase, 2011 57Figure 39: Implications for Future Market Competition in the UTI Therapeutics Market, 2011 58Figure 40: UTI Therapeutics Market - Clinical Pipeline by Company, 2011 59Figure 41: GlobalData Market Forecasting Model 70

Companies mentioned

AstraZeneca PLC

Cubist Pharmaceuticals

Forest Laboratories

To order this report: Urinary Tract Infections (UTI) Therapeutics - Pipeline Assessment and Market Forecasts to 2018

Nicolas Bombourg
Reportlinker
Email: [email protected]
US: (805)652-2626
Intl: +1 805-652-2626

SOURCE Reportlinker

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
In today's uber-connected, consumer-centric, cloud-enabled, insights-driven, multi-device, global world, the focus of solutions has shifted from the product that is sold to the person who is buying the product or service. Enterprises have rebranded their business around the consumers of their products. The buyer is the person and the focus is not on the offering. The person is connected through multiple devices, wearables, at home, on the road, and in multiple locations, sometimes simultaneously...
Basho Technologies has announced the latest release of Basho Riak TS, version 1.3. Riak TS is an enterprise-grade NoSQL database optimized for Internet of Things (IoT). The open source version enables developers to download the software for free and use it in production as well as make contributions to the code and develop applications around Riak TS. Enhancements to Riak TS make it quick, easy and cost-effective to spin up an instance to test new ideas and build IoT applications. In addition to...
Identity is in everything and customers are looking to their providers to ensure the security of their identities, transactions and data. With the increased reliance on cloud-based services, service providers must build security and trust into their offerings, adding value to customers and improving the user experience. Making identity, security and privacy easy for customers provides a unique advantage over the competition.
CenturyLink has announced that application server solutions from GENBAND are now available as part of CenturyLink’s Networx contracts. The General Services Administration (GSA)’s Networx program includes the largest telecommunications contract vehicles ever awarded by the federal government. CenturyLink recently secured an extension through spring 2020 of its offerings available to federal government agencies via GSA’s Networx Universal and Enterprise contracts. GENBAND’s EXPERiUS™ Application...
"We've discovered that after shows 80% if leads that people get, 80% of the conversations end up on the show floor, meaning people forget about it, people forget who they talk to, people forget that there are actual business opportunities to be had here so we try to help out and keep the conversations going," explained Jeff Mesnik, Founder and President of ContentMX, in this SYS-CON.tv interview at 18th Cloud Expo, held June 7-9, 2016, at the Javits Center in New York City, NY.
SYS-CON Events announced today that Isomorphic Software will exhibit at DevOps Summit at 19th International Cloud Expo, which will take place on November 1–3, 2016, at the Santa Clara Convention Center in Santa Clara, CA. Isomorphic Software provides the SmartClient HTML5/AJAX platform, the most advanced technology for building rich, cutting-edge enterprise web applications for desktop and mobile. SmartClient combines the productivity and performance of traditional desktop software with the simp...
"When you think about the data center today, there's constant evolution, The evolution of the data center and the needs of the consumer of technology change, and they change constantly," stated Matt Kalmenson, VP of Sales, Service and Cloud Providers at Veeam Software, in this SYS-CON.tv interview at 18th Cloud Expo, held June 7-9, 2016, at the Javits Center in New York City, NY.
I wanted to gather all of my Internet of Things (IOT) blogs into a single blog (that I could later use with my University of San Francisco (USF) Big Data “MBA” course). However as I started to pull these blogs together, I realized that my IOT discussion lacked a vision; it lacked an end point towards which an organization could drive their IOT envisioning, proof of value, app dev, data engineering and data science efforts. And I think that the IOT end point is really quite simple…
Redis is not only the fastest database, but it is the most popular among the new wave of databases running in containers. Redis speeds up just about every data interaction between your users or operational systems. In his session at 19th Cloud Expo, Dave Nielsen, Developer Advocate, Redis Labs, will share the functions and data structures used to solve everyday use cases that are driving Redis' popularity.
Internet of @ThingsExpo, taking place November 1-3, 2016, at the Santa Clara Convention Center in Santa Clara, CA, is co-located with the 19th International Cloud Expo and will feature technical sessions from a rock star conference faculty and the leading industry players in the world and ThingsExpo Silicon Valley Call for Papers is now open.
You think you know what’s in your data. But do you? Most organizations are now aware of the business intelligence represented by their data. Data science stands to take this to a level you never thought of – literally. The techniques of data science, when used with the capabilities of Big Data technologies, can make connections you had not yet imagined, helping you discover new insights and ask new questions of your data. In his session at @ThingsExpo, Sarbjit Sarkaria, data science team lead ...
To leverage Continuous Delivery, enterprises must consider impacts that span functional silos, as well as applications that touch older, slower moving components. Managing the many dependencies can cause slowdowns. See how to achieve continuous delivery in the enterprise.
WebRTC is bringing significant change to the communications landscape that will bridge the worlds of web and telephony, making the Internet the new standard for communications. Cloud9 took the road less traveled and used WebRTC to create a downloadable enterprise-grade communications platform that is changing the communication dynamic in the financial sector. In his session at @ThingsExpo, Leo Papadopoulos, CTO of Cloud9, discussed the importance of WebRTC and how it enables companies to focus...
"My role is working with customers, helping them go through this digital transformation. I spend a lot of time talking to banks, big industries, manufacturers working through how they are integrating and transforming their IT platforms and moving them forward," explained William Morrish, General Manager Product Sales at Interoute, in this SYS-CON.tv interview at 18th Cloud Expo, held June 7-9, 2016, at the Javits Center in New York City, NY.
Up until last year, enterprises that were looking into cloud services usually undertook a long-term pilot with one of the large cloud providers, running test and dev workloads in the cloud. With cloud’s transition to mainstream adoption in 2015, and with enterprises migrating more and more workloads into the cloud and in between public and private environments, the single-provider approach must be revisited. In his session at 18th Cloud Expo, Yoav Mor, multi-cloud solution evangelist at Cloudy...